A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy

Trial Profile

A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Bupivacaine/meloxicam (Primary) ; Bupivacaine
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Acronyms EPOCH 2
  • Sponsors Heron Therapeutics
  • Most Recent Events

    • 09 Aug 2017 The results of this trial will support an NDA that Heron expects to file in 2018, according to a company media release.
    • 01 Aug 2017 Status changed from planning to recruiting.
    • 05 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top